Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Bill & Melinda Gates Foundation Trust’s Latest Bet on China & Two Other Latest Hedge Fund Moves

Page 1 of 2

At Insider Monkey, we focus mainly on the 13F filings of around 730 hedge funds and other institutional investors, in order to identify trading opportunities and benefit from them. However, we also follow the day-to-day moves that the investors we track disclose in their filings with the Securities and Exchange Commission and investor letters. In this article, we are going to take a look at three new positions that have been recently initiated by Bill & Melinda Gates Foundation Trust, Broadfin Capital, and Newtyn Management.

As stated earlier, we analyze 13F filings of over 730 investors in order to identify some profitable stocks to invest in. We concentrate on a small group of small-cap equities that the funds we track are collectively the most bullish on and this approach has allowed us to consistently beat the market over the last three years and to generate returns of around 102%, which is 53 percentage points above the market (see more details here).

With this in mind, let’s start by taking a look at the new position that has been added to the equity portfolio of Bill & Melinda Gates Foundation Trust. The trust managed by Michael Larson in the role of Chief Investment Officer, usually adopts a conservative approach to its investments and has a relatively low turnover ratio, which makes its recent purchase even more noteworthy. In a new 13G filing, the Trust reported a new stake in China Fund Inc (NYSE:CHN) that contains 786,199 shares, equal to 5% of the company’s outstanding stock. China Fund is engaged in investment in companies in China. The closed-end management investment company invests in a variety of industries, such as commercial services, food products and healthcare. The economic slowdown in China has affected China Fund Inc (NYSE:CHN)’s performance, sending it 15% in the read in year-to-date terms, while the Net Asset Value of the fund has slipped by around 5%. Therefore, Michael Larson might be betting on the stock to gain ground on the back of a rebound of the economy in China and decided to profit from the stock’s decline. However, aside from the Bill & Melinda Gates Foundation Trust, none of the funds from our database have reported holding positions in China Fund Inc (NYSE:CHN).

Michael Larson
Michael Larson
Bill & Melinda Gates Foundation Trust

On the next page, we are going to take a closer look at Broadfin Capital’s new stake in Nexvet Biopharma plc (NASDAQ:NVET) and Newtyn Management’s latest investment in CSW Industrials Inc (NASDAQ:CSWI).

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!